
The use of zzso a zzso zzso against vascular zzso growth factor zzso in combination with standard therapeutic approaches, has offered clinical benefit for patients with advanced zzso breast, zzso zzso non zzso lung cancer and zzso However, the strategy of administering zzso until disease progression has been challenged by certain zzso evidence, suggesting that prolonged exposure to zzso treatment may elicit an zzso response, resulting in a more aggressive tumor zzso Moreover, the use of zzso in zzso zzso regimens has led to less promising results than zzso Despite our poor understanding of how zzso acts in zzso disease, numerous clinical trials zzso zzso cancer zzso are ongoing or are planned to test the therapeutic benefit in the zzso zzso The zzso of zzso efficiency in the two settings calls into question the zzso of current strategies that use similar treatment regimens for early and advanced zzso zzso we review the mechanisms of zzso activity in the zzso as compared to the zzso environment and discuss possible alternative strategies in the zzso setting that might spur attention for future clinical zzso Rather than providing an zzso survey of the literature, we highlight exemplary zzso 

